Share this:
Could blocking a testosterone receptor lead to a new way of treating an aggressive form of breast cancer? Researchers at Mayo Clinic in Arizona and The Translational Genomics Research Institute (TGen) are exploring this very question.
Preliminary results of the Mayo Clinic-TGen collaborative study show that the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).
TNBC is highly aggressive and affects approximately 10 to 20 percent of breast cancer patients. The disease is characterized by larger, faster-growing tumors than other types of breast cancer and has limited treatment options.
Surgical oncologist and lead researcher Barbara Pockaj, M.D., is presenting these results today at the 65th annual Society of Surgical Oncology conference in Orlando, Fla.
Click here for entire news release.
Soundbites from lead researcher, Barbara Pockaj, M.D., are available in the downloads above.
Expert title: Barbara Pockaj, M.D., Mayo Clinic Surgical Oncologist
Share this:
Related articles
ROCHESTER, Minn. — March is Myeloma Awareness Month, and Sikander Ailawadhi, M.D., hematologist/oncologist at Mayo Clinic Comprehensive Cancer Center, shares details about new advancements in ...
More than 50,000 people in the U.S. are diagnosed with kidney cancer each year. Risks factors for developing this type of cancer include environmental exposures, ...
Colorectal cancer is a cancer of the lower digestive system, which includes the colon and the rectum. If you feel like you are hearing a ...